Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA 2010 Results Marred By Cladribine And Poor OTC Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

Millipore acquisition boosts 2010 results for Germany's Merck, but pharma strategy remains unclear.

You may also be interested in...



Merck KGaA Chairman Karl-Ludwig Kley Says Industry Model Not Broken: An Interview With PharmAsia News (Part 2 of 2)

Merck KGaA Global Chariman Karl-Ludwig Kley, while soft-spoken, is fiercely determined to make a lasting impact for stakeholders. Kley contradicts commonly expressed views within the pharma industry on the challenges confronting the industry. At 60, Kley has gathered vast experience across industries having worked at Siemens AG before moving into the pharmaceutical industry with a job at Bayer AG back in 1982. In 2006, Kley joined Merck and a year later he was appointed as its Chairman. On his recent visit to India, he spoke to PharmAsia News' India Bureau on a range of subjects related to the global industry and the shape of emerging markets. In part one of this interview, Kley discussed challenges facing the industry and the role that emerging markets can play. In this second part, he discusses Merck KGaA's pipeline and how the company is positioning itself on the global stage.

Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter

The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.

Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter

The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel